The PURA Elements line of products is designed to provide cannabinoids with advanced delivery mechanisms in order to achieve the highest level of absorption possible into the bloodstream (bioavailability). Our team of expert scientists together with several medical and academic institutions within the USA and Canada are currently moving forward with all levels of quality control testing and pre-clinical trials. With the current shift in research now supporting the medical benefits of cannabis, our team is excited to be at the front line of cannabinoids product development.

Cannabis & Cannabinoids

Cannabis is found in two major subspecies, Cannabis indica and Cannabis sativa, that differ in their cannabinoid content. Cannabinoids themselves are the chemical compounds found in the plant that act upon cannabinoid receptors within the human endocannabinoid system [1,2,3,4].  This system exists throughout the central nervous system, immune system and sparsely throughout the entire body, and its activation induces sensations that include euphoria and relief of pain. From early Chinese medicine and throughout early Western medicine, cannabis has been acknowledged for its uses in relieving symptoms including pain, constipation, inflammation and muscle spasms [5, 6], however, it has been the recent advancement in modern biotechnology and research that the true spectrum of cannabinoid’s medicinal benefits has begun to unravel, specifically for Tetrahydrocannabinol (THC) and Cannabidiol (CBD) [1,3,4,6,7].


THC is one of the primary chemical components of cannabis and is responsible for the majority of the psychological effects brought on by cannabis use [6,8].  THC itself has been shown to reduce symptoms such as nausea, vomiting, and insomnia, as well as a wide range of other symptoms in patients suffering from ailments including chronic pain and HIV/AIDS [1,6,7,8,9]. It has been shown to effectively help against stress, arthritis, as well as other related symptoms for those living with Multiple Sclerosis (MS) [1,8,10,11], Parkinson’s disease [12,13], and various cancers including glaucoma [1,5,8].  Emerging research has indicated a high therapeutic potential for a variety of other health concerns, often demonstrating therapeutic benefit at doses below the psychoactive threshold.


CBD is another major cannabinoid found in cannabis. Unlike THC, CBD does not demonstrate the same psychoactive effects and has been better suited to treat symptoms associated with diabetes [3,14], cancers [1,4,14], mood disorders including PTSD, ADD, OCD [1,7,13], and inflammatory diseases such as arthritis [1,3,14,15,16], and inflammatory bowl syndrome (IBS) and disease (IBD)  [1,2,14,17,18].  Most notably, CBD has gained attention for its effective treatment against epilepsy [1,4,7] however is has demonstrated targets beyond this including benefits towards obesity and addictions to smoking (tobacco cigarettes) [1,2,19,20,21].  The lack of psychoactive response coupled with its positive therapeutic effects makes CBD a desirable choice for many individuals seeking cannabinoid therapies while remaining sharp and clear headed.

Summary: Therapeutic & Medical

There has been an increasing amount of reported research that substantiates the medicinal benefits of cannabis, specifically its cannabinoids constituents THC and CBD.  Currently (and as provided by Health Canada [1]), there exists an enormous collection of data generated through clinical and pre-clinical trials, as well as in vitro, observational and experimental research data that supports the positive use of cannabinoids for a variety of medical conditions that surpass the information presented here.

[1] Health Canada (2013) Information for Health Care Professionals: Cannabis (marijuana, marijuana).
[2] Fine PG, Rosenfeld MJ (2013) The Endocannabinoid System, Cannabinoids, and Pain. Rambam Maimonides Med J. 4 DOIe0022
[3] Atakan Z (2012) Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2: 241-254
[4] Morabito D et al. (2016) A Review of Recent Advances in the Therapeutic Uses of Secondary Cannabinoids. Curr Addict Rep 3: 230-238
[5] Abrams DI, Guzman M (2015) Cannabis in Cancer Care. Clin Pharmacol Ther 6: 575-86
[6] Robson PJ (2013) Therapeutic potential of cannabinoid medicine. Drug Test Anal 6: 24-30
[7] Baron EP (2015) Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been… Head Curr 885-916
[8] Klein TW (2005) Cannabinoid-based drugs as ant-inflammatory therapeutics.
Nat Rev Immunol 5: 400-411
[9] D’Souza G et al. (2012) Medicinal and Recreational Marijuana Use Among HIV-Infected Women in the Women’s Interagency HIV Study (WIHS) Cohort, 1994–2010. Epid Prev 61: 618-626
[10] Pozzilli P (2013) Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev 13: 49-54
[11] Notcutt WG (2015) Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. NeuroTher 12: 769-777
[12] Campos AC et al. (2012) Cannabidiol blocks long-
lasting behavioral consequences of predator threat stress: possible
involvement of 5HT1A receptors. J Psychiatr Res 46: 1501–1510
[13] Blessing EM et al. (2015) Cannabidiol as a Potential Treatment for Anxiety Disorders. NeuroTher 12: 825-836
[14] Izzo A (2004) Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142: 1201–1202
[15] Malfait AM et al. (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci 97: 9561–9566
[16] Sumariwalla PF et al. (2004) A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum
50: 985–998
[17] Massa F et al. (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202–1209
[18] Mathison R et al. (2004) Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 142: 1247–1254
[19] Black SC (2004) Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5: 389–394
[20] Foulds J et al. (2004) Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 9: 39–53
[21] Howlett AC et al. (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47: 345–358
Loading posts...
Sort Gallery
Enter your email here